Burning Rock Biotech Ltd. (BNR)
NASDAQ:BNR

Burning Rock Biotech Stock Analysis & Ratings

BNR Stock Chart & Stats

Day’s Range$2.9 - $3.2
52-Week Range$2.90 - $38.64
Previous Close$3.09
Volume417.76K
Average Volume (3M)305.17K
Market Cap$306.10M
P/E Ratio-2.5
Beta-0.33
Next EarningsMay 31, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score7
EPS (TTM)-1.19


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

BNR FAQ

What was Burning Rock Biotech’s price range in the past 12 months?
Burning Rock Biotech lowest stock price was $2.90 and its highest was $38.64 in the past 12 months.
    What is Burning Rock Biotech’s market cap?
    Burning Rock Biotech’s market cap is $306.10M.
      What is Burning Rock Biotech’s price target?
      The average price target for Burning Rock Biotech is $12.80. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $12.80 ,the lowest forecast is $12.80. The average price target represents 339.86% Increase from the current price of $2.91.
        What do analysts say about Burning Rock Biotech?
        Burning Rock Biotech’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Burning Rock Biotech’s upcoming earnings report date?
          Burning Rock Biotech’s upcoming earnings report date is May 31, 2022 which is in 8 days.
            How were Burning Rock Biotech’s earnings last quarter?
            Burning Rock Biotech released its earnings results on Mar 22, 2022. The company reported -$0.359 earnings per share for the quarter, missing the consensus estimate of -$0.224 by -$0.135.
              Is Burning Rock Biotech overvalued?
              According to Wall Street analysts Burning Rock Biotech’s price is currently Undervalued.
                Does Burning Rock Biotech pay dividends?
                Burning Rock Biotech does not currently pay dividends.
                What is Burning Rock Biotech’s EPS estimate?
                Burning Rock Biotech’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Burning Rock Biotech have?
                Burning Rock Biotech has 105,190,000 shares outstanding.
                  What happened to Burning Rock Biotech’s price movement after its last earnings report?
                  Burning Rock Biotech reported an EPS of -$0.359 in its last earnings report, missing expectations of -$0.224. Following the earnings report the stock price went up 5.317%.
                    Which hedge fund is a major shareholder of Burning Rock Biotech?
                    Among the largest hedge funds holding Burning Rock Biotech’s share is ARK Investment Management LLC. It holds Burning Rock Biotech’s shares valued at 33M.

                      ---

                      Burning Rock Biotech Stock Analysis

                      The Burning Rock Biotech stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Burning Rock Biotech Ltd.

                      Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and LungPlasma. The company has developed various cancer detection products , involving tumor targeting, oncomitant diagnosis of immune drugs, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress and detection of tumor sensitivity.

                      ---
                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis